ARTICLE | Financial News
Visudyne sales fall 10%
April 25, 2006 1:19 AM UTC
Novartis (NVS; SWX:NOVN) reported first quarter sales of Visudyne verteporfin photodynamic therapy of $107 million, down 10% from the prior year's quarter. NVS attributed the lower sales to off-label ...